Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

Core Insights - Editas Medicine, Inc. plans to announce its Q4 and Full Year 2024 financial results and business updates on March 5, 2025, via press release and SEC filings, and will not host quarterly financial results conference calls in the future [1] - The company will participate in several upcoming investor conferences in March, including the TD Cowen 45th Annual Health Care Conference, the Leerink Partners Global Healthcare Conference, and the Barclays 27th Annual Global Healthcare Conference, all formatted as fireside chats [2] Company Overview - Editas Medicine is a pioneering gene editing company focused on developing transformative in vivo medicines using CRISPR/Cas12a and CRISPR/Cas9 genome editing systems for serious diseases [3] - The company aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases and holds exclusive licenses for key patents from the Broad Institute and Harvard University [3]